Intralesional injections of Citoprot‐P(®) (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation

To investigate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) in advanced diabetic foot ulcers (DFU) A double‐blind trial was carried out to test two rhEGF dose levels in type 1 or 2 diabetes patients with Wagner’s grade 3 or 4 ulcers, with high risk of amputation. Subj...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int Wound J
Auteurs principaux: Fernández‐Montequín, José I, Infante‐Cristiá, Ena, Valenzuela‐Silva, Carmen, Franco‐Pérez, Neobalis, Savigne‐Gutierrez, William, Artaza‐Sanz, Heriberto, Morejón‐Vega, Lourdes, González‐Benavides, Cecilio, Eliseo‐Musenden, Osvaldo, García‐Iglesias, Elizeth, Berlanga‐Acosta, Jorge, Silva‐Rodríguez, Ricardo, Betancourt, Blas Y, López‐Saura, Pedro A
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2007
Sujets:
Clinical Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7951380/
https://ncbi.nlm.nih.gov/pubmed/17953679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1742-481X.2007.00344.x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires